CELT publications
You can refine your search results by using the keyword search function.
| Publication date (day/month/year) |
Title | Keywords | Authors | Journal |
|---|---|---|---|---|
| 2023-11-30 | PBPK, modelling, cabotegravir, Microarray patches | Kinvig, H., Rajoli, R.K.R., Pertinez, H., Vora, L.K., Volpe-Zanutto, F., Donnelly, R.F., Rannard, S., Flexner, C., Siccardi, M., & Owen A. | Pharmaceutics | |
| 2023-10-27 | sars-cov-2 | Gallardo-Toledo, E., Neary, M., Sharp, J., Herriott, J., Kijak, E., Bramwell, C., Curley, P., Arshad, U., Pertinez, H., Rajoli, R.K.R., Valentijn, A., Cox, H., Tatham, L., Kipar, A., Stewart, J., & Owen, A. | Viruses | |
| 2023-08-15 |
Evaluation of Nafamostat as Chemoprophylaxis for SARS-CoV-2 Infection in Hamsters |
nafamostat, sars-cov-2 | Neary, M., Sharp, J., Gallardo-Toledo, E., Herriott, J., Kijak, E., Bramwell, C., Cox, H., Tatham, L., Box, H., Curley, P., Ashad, U., Rajoli, R.K.R, Pertinez, H., Valentijn, A., Dhaliwal, K., Mc Caughan, F., Hobson, J., Rannard, S., Kipar, A., Stewart, J., & Owen, A. | Viruses |
| 2023-06-27 |
Preclinical Evaluation of Long-Acting Emtricitabine Semi-Solid Prodrug Nanoparticle Formulations |
emtricitabine, prodrug, nanoparticle formulations | Curley, P., Hobson, J., Lipptrott, N.J., Makarov, E., Al-Khouja, A., Tatham, L., David, C.A.W., Box, H., Neary, M., Sharp, J., Pertinez, H., Meyers, D., Flexner, C., Freel Meyers, C.L., Poluektova, L., Rannard, S., & Owen, A. | Pharmaceutics |
| 2023-06-14 | rifapentine, rifabutin, tuberculosis | Yong, S.C., Li, S.Y., Pertinez, H., Betoudji, F., Lee, J., Rannard, S., Owen, A., Nuermberger, E.L., & Ammerman, N.C. | Antimicrobial Agents and Chemotherapy | |
| 2023-03-09 | Ronapreve, sara-cov-2 | Tatham, L., Kipar, A., Sharp, J., Kijak, E., Herriott, J., Neary, M., Box, H., Gallardo Toledo, E., Valentijn, A., Cox, H., Pertinez, H., Curley, P., Arshad, U., Rajoli, R.K.R, Rannard, S., Stewart, J., & Owen, A. | bioRxiv | |
| 2022-12-05 |
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2 |
fxr inhibitor, sars-cov-2, ace2 | Brevini, T., Maes, M., Webb, G. J., John, B. V., Fuchs, C. D., Buescher, G., Sampaziotis, F. | Nature |
| 2022-11-21 | Flexner, C., Siccardi, M., Bunglawala, F., & Owen, A. | Clinical Infectious Diseases | ||
| 2022-11-21 | Prospects for Long-Acting Treatments for Hepatitis C | Thomas, D. L., Owen, A., & Kiser, J. J. | Clinical Infectious Diseases | |
| 2022-11-21 | Potential Impact of Long-Acting Products on the Control of Tuberculosis: Preclinical Advancements and Translational Tools in Preventive Treatment | Ammerman, N. C., Nuermberger, E. L., Owen, A., Rannard, S. P., Meyers, C. F., & Swindells, S. | Clinical Infectious Diseases | |
| 2022-11-21 | Neary, M., Owen, A., & Olagunju, A. | Clinical Infectious Diseases | ||
| 2022-11-10 |
WHO Living Guidelines on antivirals for COVID-19 are evidence-based |
antiviral, covid | Owen, A., Diaz, J. V., Guyatt, G., Lamontagne, F., Stegemann, M., Vandvik, P. O., & Agoritsas, T. | The Lancet |
| 2022-11-01 | Chandiwana, N., Kruger, C., Johnstone, H., Chughlay, M. F., Ju, C., Kim, B., . . . Venter, W. D. F. | eBio Medicine | ||
| 2022-10-12 | Hentzien, M., Owen, A., Strub-Wourgaft, N., Perez-Casas, C., Troseid, M., & Calmy, A | Frontiers in Microbiology | ||
| 2022-09-30 | Simiso Sokhela; Bronwyn Bosch; Andrew Hill; Bryony Simmons; Joana Woods; Hilary Johnstone; Godspower Akpomiemie; Leah Ellis; Andrew Owen; Carmen Perez Casas et al. | Journal of Antimicrobial Chemotherapy | ||
| 2022-09-22 | covid, favipiravir | Sirijatuphat, R., Manosuthi, W., Niyomnaitham, S., Owen, A., Copeland, K. K., Charoenpong, L., Chokephaibulkit, K | Emerging Microbes and Infections | |
| 2022-08-12 | Frauke Assmus; Jean-Sélim Driouich; rana abdelnabi; Laura Vangeel; Franck Touret; Ayorinde Adehin; Palang Chotsiri; Maxime Cochin; Caroline S. Foo; DIRK JOCHMANS, Andrew Owen, et al | Microorganisms | ||
| 2022-05-19 | Neill Liptrott, Tom McDonald, Andrew Owen, Steve Rannard, et al. | Journal of Materials Chemistry B | ||
| 2022-05-11 |
Neuroinvasion and Neurotropism by SARS-CoV-2 Variants in the K18-hACE2 Mouse |
Frauke Seehusen; Jordan J. Clark; Parul Sharma; Eleanor G. Bentley; Adam Kirby; Krishanthi Subramaniam; Sabina Wunderlin-Giuliani; Grant Hughes; Edward Patterson; Benedict Michael, Andrew Owen et al. | Viruses | |
| 2022-02-11 |
Unlike Chloroquine, Mefloquine Inhibits SARS-CoV-2 Infection in Physiologically Relevant Cells |
Carolina Q. Sacramento, Natalia Fintelman-Rodrigues, Suelen S. G. Dias, Jairo R. Temerozo, Aline de Paula D. Da Silva, Carine S. da Silva, Camilla Blanco, André C. Ferreira, Mayara Mattos, Vinicius C. Soares, Filipe Pereira-Dutra, Milene Dias Miranda, Debora F. Barreto-Vieira, Marcos Alexandre N. da Silva, Suzana S. Santos, Mateo Torres, Otávio Augusto Chaves, Rajith K. R. Rajoli, Alberto Paccanaro, Andrew Owen, Dumith Chequer Bou-Habib, Patrícia T. Bozza, Thiago Moreno L. Souza |
Viruses | |
|
2022-02-11 |
LC-MS/MS, Cervicovaginal fluid, Swab, Pharmacokinetics, Efavirenz |
|
Wellcome Open Research | |
| 2021-11-30 |
|
Journal of Materials Chemistry B | ||
| 2021-10-26 |
Preferences of Persons with or at Risk for Hepatitis C for Long-Acting Treatments |
Hepatitis C Long-Acting Treatments Patient Preferences Medication Acceptability Novel Drug Delivery Methods. |
Rothman R, Solomon SS, Matthews GV, Hsieh YH, Verma M, |
Clinical Injectious Diseases |
| 2021-09-11 | nitazoxanide, antiviral, sars-cov-2 |
, , , , , , , , |
medRxiv | |
| 2021-06-25 | Drug delivery systems as immunomodulators for therapy of infectious disease: Relevance to COVID-19 | COVID-19, SARS-CoV-2, Inflammasome, Complement, Nanomedicine, Endothelium |
Christopher David, Christian Hedrich, Andrew Owen, Neill J. Liptrott |
Advanced Drug Delivery Review |
| 2021-03-20 | Scalable nanoprecipitation of niclosamide and in vivo demonstration of long-acting delivery after intramuscular injection | niclosamide, intramuscular |
J. Hobson, A. Savage, A. Dwyer, C. Unsworth, J. Massam, U. |
Nanoscale |
| 2021-01-01 | Long-acting drugs and formulations for the treatment and prevention of HIV infection | HIV, prevention | Flexner C, Owen A, Siccardi M, Swindells S. | International journal of Antimicrobial Agents |
| 2020-11-20 | Chasing COVID-19 chemotherapeutics without putting the cart before the horse | COVID-19, chemotherapeutics | Steve Rannard, Tom McDonald & Andrew Owen | British Journal of Clinical Pharmacology |
| 2020-07-22 | Predicting Pharmacokinetics of a Tenofovir Alafenamide Subcutaneous Implant Using Physiologically Based Pharmacokinetic Modelling | pharmacokinetics, tenofovir, alfenamide, subcutaneous, implant | Rajoli RKR, Demkovich ZR, Flexner C, Owen A, Siccardi M. | Antimicrobial Agents and Chemotherapy |
| 2020-06-16 | Pharmacokinetics of HIV therapies in pregnant patients: an update | pharmacokinetics, HIV, pregnant | Neary M, Owen A, Olagunju A. | Expert opinion on Drug Metabolism & Toxicology |
| 2019-10-12 | Anhydrous nanoprecipitation for the preparation of nanodispersions of tenofovir disoproxil fumarate in oils as candidate long-acting injectable depot formulations | anhydrous, nanoprecipitation, nanodispersions, tenofovir, disoproxil, fumurate, oil |
J. Hobson, P. Curley, A. Savage, A. Al-khouja, M. Siccardi, |
Nanoscale Advances |
| 2019-09-13 | Modelling the intradermal delivery of microneedle array patches for long-acting antiretrovirals using PBPK | microneedle, array, patch, antiretroviral, PBPK |
Rajoli RKR, Flexner C, Chiong J, Owen A, Donnelly RF, |
European Journal of Pharmaceutics and Biopharmaceutics |
| 2019-07-29 | Long-Acting Injectable Statins-Is It Time for a Paradigm Shift? | statins | Tatham LM, Liptrott NJ, Rannard SP, Owen A. | Molecules |
| 2019-05-05 | Predicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic Modeling | drug-drug, rifampicin, cabotegravir, rilpivirinet, pharmacokinetic, modeling, pharmacokinetics |
Rajoli RKR, Curley P, Chiong J, Back D, Flexner C, |
The Journal of Infectious Diseases |
| 2019-05-01 | Towards a Maraviroc long-acting injectable nanoformulation | maraviroc |
Lee M.Tathama, Alison C. Savage, Andrew Dwyer, |
European Journal of Pharmaceutics and Biopharmaceutics |
| 2019-03-29 | Semi-solid prodrug nanoparticles for long-acting delivery of water-soluble antiretroviral drugs within combination HIV therapies | semi-solid, prodrug, nanoparticles, water-soluble, antiretroviral, HIV |
James J. Hobson, Amer Al-khouja, Paul Curley, |
Nature Communications |
| 2018-08-01 | Modelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept study | tuberculosis, PBPK, proof of concept |
Rajoli RKR, Podany AT, Moss DM, Swindells S, Flexner C, |
The International Journal of Tuberculosis and Lung Disease |
| 2018-06-16 | The emerging role of physiologically based pharmacokinetic modelling in solid drug nanoparticle translation | pharmacokinetic, modeling, solid drug, nanoparticle | Siccardi M, Rannard S, Owen A. | Advanced Drug Delivery Reviews |
| 2018-03-15 | Assessment of interactions of efavirenz solid drug nanoparticles with human immunological and haematological systems | efavirenz, solid drug, nanoparticle, haematological | Liptrott NJ, Giardiello M, McDonald TO, Rannard SP, Owen A. | Journal of Nanobiotechnology |
| 2018-02-09 | Modulated Release from Implantable Ocular Silicone Oil Tamponade Drug Reservoirs | modulated release, implant, ocular silicone, oil, tamponade |
Helen Cauldbeck , Maude Le Hellaye, Tom O. McDonald , Mark Long, |
Journal of Polymer Science |
| 2018-02-01 | Long-acting formulations for the treatment of latent tuberculous infection: opportunities and challenges | latent, tuberculosis, TB |
Swindells S, Siccardi M, Barrett SE, Olsen DB, Grobler JA, Podany AT, |
The International Journal of Tuberculosis and Lung Disease |
| 2018-01-22 | Long-acting injectable atovaquone nanomedicines for malaria prophylaxis | atovaquone, nanomedicines, malaria, prophylaxis |
R. Bakshi, L. Tatham, A. Savage, A. Tripathi, G. Mlambo, M. Ippolito, |
Nature Communications |
| 2017-09-06 | Advances in nanomedicine drug delivery applications for HIV therapy | HIV, drug delivery | Curley P, Liptrott NJ, Owen A. | Future Science OA |
| 2017-05-24 | In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents | In silico, dose prediction, rilpivirine, cabotegravir, children, adolescents |
Rajith K. R. Rajoli, David J. Back, Steve Rannard, Caren Freel Meyers, |
Clinical Pharmacokinetics |
| 2016-12-28 | Controlling drug release from non-aqueous environments: Moderating delivery from ocular silicone oil drug reservoirs to combat proliferative vitreoretinopathy | non-aqueous, ocular, silicone, oil, proliferative, vitreoretinopathy |
Helen Cauldbeck, Maude Le Hellayea, Mark Long, Stephnie M. Kennedy, |
Journal of Controlled Release |
| 2016-12-10 | Drug delivery strategies and systems for HIV/AIDS pre-exposure prophylaxis and treatment | HIV, AIDS, pre-exposure, prophylaxis | Nelson AG, Zhang X, Ganapathi U, Szekely Z, Flexner CW, Owen A, Sinko PJ. | Official Journal of the Controlled Release Society |
| 2016-08-01 | Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy | HIV, therapy | Andrew Owen, Steve Rannard | Advanced Drug Delivery Reviews |
| 2015-06-05 | Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV | physiology, Pharmacokinetic, modeling, intramuscular, nanoformulations, HIV | Rajoli RK, Back DJ, Rannard S, Freel Meyers CL, Flexner C, Owen A, Siccardi M. | Clinical Pharmacokinetics |
| 2014-01-07 | New approaches to antiretroviral drug delivery: challenges and opportunities associated with the use of long-acting injectable agents | drug delivery, long-acting, injectible | Boffito M, Jackson A, Owen A, Becker S. | Drugs |